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Purpose: Congestive heart failure (CHF) is one of the risk factors for deep vein thrombosis (DVT) according
to the Japanese guidelines for DVT treatment and prevention. The purpose of this study is to estimate
the frequency of DVT among hospitalized CHF patients, since there have been only limited DVT data in
Japanese CHF patients.
Methods: Patients enrolled in the study were with risk factors for DVT listed in the guidelines as well as
with acute exacerbation of CHF, bed rest for at least 4 days, and aged60or above. Patients treated byphys-
ical prophylaxis or anti-platelet medication were included, while patients treated by any anticoagulant
medicines were excluded. Patients with surgery or injury within 3 months before the hospitalization
or diagnosed clinically or with obvious past history as having DVT at hospitalization were excluded.
The presence of DVT in the eligible patients was determined by ultrasonography and the images were
evaluated by an independent central evaluation committee.
Results: Forty-four patients were enrolled in the study including 19 males and 25 females. The mean age
was 79.0±10.6 years, and the mean duration of bed rest was 8.9±3.2 days. Out of these 44 patients,
DVT was detected in 15 (34%) patients. Eight patients were on treatment with physical prophylaxis but
DVT was still detected in two patients. Furthermore, 12 out of the rest of the patients were treated by
anti-platelet agents and were still with DVT in 3 patients.
Conclusion: When evaluated ultrasonographically, the frequency of DVT in hospitalized non-surgical
Japanese patients with CHF was approximately 35%. DVT occurred in 25% of patients treated by physical
prophylaxis or anti-platelet agents. The results suggest that Japanese hospitalized patientswith CHF have
a high risk of DVT and thus can be recognized to have potential beneﬁt by preventing and treating DVT
according to the guidelines.
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.∗ Correspondingauthor at:MatsuoVascularUltrasoundLaboratory,MatsuoClinic,
6-9 Enoki-cho, Suita 564-0053, Japan. Tel.: +81 6 6388 0041; fax: +81 6 6388 0166.
E-mail address: hiro-matu@fan.hi-ho.ne.jp (H. Matsuo).
ttp://dx.doi.org/10.1016/j.jjcc.2014.02.028
914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reIntroductionIn Japan, the frequency of deep vein thrombosis (DVT) was rec-
ognized as being lower than that overseas [1]. However recent
reports suggest that the frequency of DVT in Japanese can be
assumed similar to that in Westerners. The frequencies of DVT in
served.
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reproducible and reliable. The training meeting of diagnosis proce-
dure for investigators and medical technologists was implemented
before starting the study. The ultrasound diagnosis was performed
between the 6th and 14th day of patient’s bed rest. If symptomatic
Table 1
Characteristics of patients with congestive heart failure (hospitalized).
Continuous parameters N Mean (SD)
Agea (years) 44 79.1 (10.6)
Body weight (kg) 44 53.3 (16.2)
BMI (kg/m2) 44 22.5 (6.4)
Systolic blood pressure (mmHg) 44 124.8 (22.5)
Diastolic blood pressure (mmHg) 44 67.4 (16.7)
Duration of rest (days) 44 8.9 (5–16)b
Categorical parameters N %
Gender: male/female 19/25 43.2/56.8
Smoking history (male): yes (current or past)/no 9/10 47.4/52.6
Smoking history (female): yes (current or past)/no 2/23 8.0/92.0
Drinking habit (male): yes (current and past)/no 11/8 57.9/42.1
Drinking habit (female): yes (current and past)/no 1/24 4.0/96.0
Fitness habit (male): yes (current and past)/no 2/17 10.5/89.5
Fitness habit (female): yes (current and past)/no 8/17 32.0/68.0
Catheterization within last 3 months: yes/no 11/33 25.0/75.0
Basic disease 44 100.0
Valvular disorder 11 25.0
Coronary artery disease 9 20.5
Myocardial disorder 9 20.5
Atrial ﬁbrillation 5 11.4
Atrioventricular block 4 9.1
Hypertensive cardiovascular disease 2 4.5
Other disease (including multiple diseases) 4 9.1
NYHA classiﬁcation
- The stages of heart failure 44 100.0
Class III (moderate) 14 31.8
Class IV (severe) 30 68.2
Physical prevention: yes/no 8/36 18.2/81.8
Medication of antiplatelet agents: yes/no 12/32 27.3/72.7
Medical history of VTE: yes/no 0/44 0.0/100.0
Concomitant disease of malignancy: yes/no 7/37 15.9/84.1
Concomitant disease of diabetes: yes/no 8/36 18.2/81.8
Concomitant disease of dyslipidemia: yes/no 11/33 25.0/75.0
Concomitant disease of hyperuricemia: yes/no 19/25 43.2/56.8
Concomitant disease of hypertension: yes/no 34/10 77.3/22.7
Concomitant disease of angina pectoris: yes/no 11/33 25.0/75.0
Concomitant disease of arrhythmia: yes/no 21/23 47.7/52.3
Concomitant disease of stroke: yes/no 7/37 15.9/84.1H. Matsuo et al. / Journal o
apanese post-operative patientswithhip replacement surgery and
nee replacement arthroplasty are 27.4% and 50.0%, respectively
2]. In Westerner, the frequencies are 42–57% for hip replacement
urgery and 41–85% for knee replacement arthroplasty [3].
It is recognized that the frequency of VTE in speciﬁc patient pop-
lation of medical practice is higher than that of surgical patients
ith mild-to-moderate risks, although the reported frequencies
ave large variance. In some studies outside of Japan, the frequen-
ies of DVT were reported to be 10–26% of general in-hospital
atients [4–6]. Especially in patients with CHF, Nicolaides et al.
7] reported the frequency reached to 40%. Based on these stud-
es, the approaches for primary prevention of VTE have already
een introduced since more than 20 years ago in USA and Europe.
urrently, the requirement of prevention for VTE is widely recog-
ized not only for post-operative patients but also for hospitalized
atients in medical practice [8].
The current Japanese prevention guideline [9] recommends
rimary prevention to some speciﬁc internal diseases including
ongestive heart failure (CHF). Ota et al. [10] reported that NYHA
lass related to increase in the VTE risk particularly in patients with
n extremely high risk for NYHA class IV in Japan. That is the reason
hy the condition of CHF with NYHA III or IV is targeted by the cur-
ent prevention guideline for primary prevention. However, as the
revention guideline noted in the introduction, very limited and
mall-scale studies are available for clarifying the actual frequency
f DVT in Japanese non-surgical patients. Since whether there is a
eneﬁt to prevent and treat hospitalized CHF patients for DVT has
een unclear so far, we aimed to estimate the frequency of DVT in
apanese patients with CHF (NYHA III and IV).
aterials and methods
Before patient enrollment, the protocol had been evaluated and
pproved by the institutional review board (IRB) or ethical com-
ittee (EC) in each medical site. The investigator explained the
urpose andmethods of the study to the patients and then received
is/her signed informed consent (IC) form before conducting any
rocedures of the study on each patient. The study was conducted
y fully following the latest version of the Declaration of Helsinki
2008). The study was fully funded by a sponsor (GlaxoSmithKline,
apan).
This study is a multi-center, prospective, epidemiological study
o estimate the frequency of DVT in hospitalized non-surgical
apanese patients with CHF.
Patients enrolled in the study were hospitalized patients iden-
iﬁed as at high risk of VTE development based on a combination of
isk factors in the prevention guideline. The inclusion criteria were
atients with: (a) acute exacerbation of CHF (III or IV of NYHA clas-
iﬁcation of cardiac performance), (b) bed rest for 4 days and more,
nd (c) 60 years old or older. The exclusion criteria were patients
ith: (a) surgery or injury within 3 months before hospitalization,
b) diagnosed clinically or with obvious past history as having DVT
t hospitalization, and (c) treated with any anticoagulants. When
atients had any underlying diseases (valvular disorder, coronary
rtery disease, myocardial disorder, atrial ﬁbrillation, atrioventric-
lar block, hypertensive cardiovascular disease, andother diseases)
nd showedany symptoms related toheart pumpdysfunction, they
ere diagnosed with congestive heart failure. We referred to Fra-
ingham criteria of the Framingham study [11] in the diagnosis.
e evaluated the severity of heart failure by the NYHA functional
lassiﬁcation, butdidnot investigate thedetailedclinical conditions
ncluding central venous pressure, left ventricular dimension, left
entricular ejection fraction, and brain natriuretic peptide level in
his study. We thus evaluated the occurrence of the DVT by the
everity of CHF by using only NYHA classiﬁcation.iology 64 (2014) 430–434 431
After getting the IC from the patient, the presence of DVT was
examined by using lower extremity ultrasonography (US) and the
following data were collected.
Collected data
Collected data include demographic variables, life style vari-
ables, general medical history, physical examination, current
medical condition, lower extremity vein US, and laboratory test
(Table 1).
Diagnosis of DVT
Imaging techniques including US, venography, magnetic reso-
nance venography, and contrast enhanced computed tomography
have been used for the evaluation of DVT. Among them, diagnosis
by US is non-invasive, and has been standardized in the guide-
line “Criteria for ultrasound diagnosis of deep venous thrombosis
of lower extremities” [12] in 2008 by the Japan Society of Ultra-
sonics in Medicine. We thus considered that diagnosis with US isBMI, body mass index; NYHA, New York Heart Association; VTE, venous throm-
boembolism.
a Age: patient’s age at the time of ultrasonic examination.
b Range (min–max).
4 f Cardiology 64 (2014) 430–434
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Table 2
Characteristics of patients with congestive heart failure classiﬁed by the presence
or absence of deep vein thrombosis (DVT).
DVT (+) (n=15) DVT (−) (n=29) p valuea
Male 6 (40.0%) 13 (44.8%)
1.000Female 9 (60.0%) 16 (55.2%)
Age (years) 75.1±9.3b 81.1±10.8 0.078
Age ≥75 years 9 (60.0%) 21 (72.4%) 0.501
Body weight (kg) 50.4±14.4 54.7±17.2 0.410
BMI (kg/m2) 21.4±6.4 23.1±6.4 0.404
BMI ≥25kg/m2 3 (20.0%) 6 (20.7%) 1.000
Systolic blood pressure
(mmHg)
127.2±26.1 123.6±20.8 0.619
Diastolic blood pressure
(mmHg)
66.5±12.1 67.8±18.8 0.801
Duration of rest (days) 9.1±3.2 8.789±3.2 0.792
Smoking history (male): yes 3 (20.0%) 6 (20.7%) 1.000
Smoking history (female): yes 1 (6.7%) 1 (3.4%) 1.000
Drinking habit (male): yes 4 (26.7%) 7 (24.1%) 1.000
Drinking habit (female): yes 1 (6.7%) 0 (0.0%) 0.360
Fitness habit: yes 4 (26.7%) 6 (20.7%) 0.714
Catheterization within last 3
months: yes
4 (26.7%) 7 (24.1%) 1.000
NYHA III 7 (46.7%) 7 (24.1%) 0.177
NYHA IV 8 (53.3%) 22 (75.9%)
Concomitant diseases
Malignancy 2 (13.3%) 5 (17.2%) 1.000
Chemotherapy for
malignancy
1 (6.7%) 2 (6.9%) 1.000
Diabetes 2 (13.3%) 6 (20.7%) 0.695
Dyslipidemia 2 (13.3%) 9 (31.0%) 0.282
Hyperuricemia 6 (40.0%) 13 (44.8%) 1.000
Paralysis 0 (0.0%) 4 (13.8%) 0.282
Hypertension 10 (66.7%) 24 (82.8%) 0.271
Angina pectoris 4(26.7%) 7 (24.1%) 1.000
Myocardial infarction 4(26.7%) 2 (6.9%) 0.159
Thrombophilia 1 (6.7%) 0 (0.0%) 0.341
Arrhythmia 5 (33.3%) 16 (55.2%) 0.102
Heart failure 15 (100%) 29 (100%) –
Stroke 2 (13.3%) 5 (17.2%) 1.000
Aortic aneurysm 1(6.7%) 2 (6.9%) 1.000
Varicose vein 0 (0.0%) 0 (0.0%) –
COPD 2(13.3%) 1 (3.4%) 0.264
Asthma 0(0.0%) 2 (6.9%) 0.540
Gastroduodenal ulcer 0 (0.0%) 1 (3.4%) 1.000
Inﬂammatory bowel
disorder
0 (0.0%) 0 (0.0%) –
Chronic hepatitis 0 (0.0%) 0 (0.0%) –
Hepatic cirrhosis 0 (0.0%) 1 (3.4%) 1.000
Nephrosis syndrome 1(6.7%) 1 (3.4%) 1.000
Hormone replacement
therapy
0 (0.0%) 0 (0.0%) –
BMI, body mass index; NYHA, New York Heart Association; COPD, chronic obstruc-
tive pulmonary disease.32 H. Matsuo et al. / Journal o
VT was suspected from the patient’s signs and symptoms, the test
as conducted at that time. The US testing portion of the lower
xtremity vein was from the ilium to the lower leg; pulmonary
hromboembolism was not evaluated in this study.
Diagnosis of new and old thrombus was performed based on
tenosis (occlusion or stenosis) and distention (distended or con-
racted) of veins, ﬂoating (free or ﬁxed), regression (none/moderate
r severe), consistency (soft or hard), surface character (smooth or
rregular), brightness (low/middle or high/middle) and homogene-
ty (homogeneous or heterogenous) of thrombus, perfusion defect
total or partial), recanalization in thrombus (absent or present),
nd collateral in branch (absent or present).
The images of the lower extremity vein US and the investiga-
or’s evaluations were sent to an independent central evaluation
ommittee. The committee uniformly evaluated and diagnosed the
resence of DVT based on these images and information.
ata analysis
The frequency of DVT was calculated by dividing the number
f patients with DVT by the number of enrolled patients. Preva-
ence of potential risk factors for DVT (obesity, bed rest, smoking,
iabetes, etc.) was compared between DVT positive and negative
roups using Fisher’s exact test or Student’s t-test.
The descriptive statistics for continuous variables show
ean± standard deviation (SD) and frequencies and percentage
or categorical variables. The results of the statistical test were
ndicated by p values with signiﬁcance level of ˛=0.05.
esults
The study started in September 2009 (ﬁrst patient enrolled) and
nded in August 2010 (last patient enrolled), and was conducted
t six medical sites (Fukushima Daiichi Hospital, Saitama Medical
niversity International Medical Center, Yokohama Minami Kyosai
ospital, Mie University Hospital, Kyoto University Hospital, and
akarazuka Municipal Hospital) involving eight principal investi-
ators.
A total of 44 patients were enrolled in the study including
9 males and 25 females, mean age of 79.1±10.6 years, and 14
YHA-IIIs and 30 NYHA-IVs (Table 1). No patient was prematurely
erminated or excluded from the data analysis.
The basic diseases of CHF for the patients were valvular dis-
ase (n=11), coronary artery disease (n=9), myocardial disorder
n=9), atrial ﬁbrillation (n=5), atrioventricular block (n=4), hyper-
ensive cardiovascular disease (n=2), and others (n=4). Symptoms
bserved most commonly among patients were orthopnea, jugular
ein, rales, and cardiac dilatation.
The frequency of DVT was 34.1% (15/44) in patients with CHF
nd its 95% conﬁdence intervalwas 20.1–48.1%. No statistically sig-
iﬁcant difference was observed between DVT positive (n=15) and
egative (n=29) groups on baseline characteristics of the patients.
he details of the characteristics of the patients classiﬁed by the
resence or absence of DVT are shown in Table 2.
The major results of comparison on prevalence for main impor-
ant parameters are shown in Table 3. It is notable that DVT
evelopment was observed in two (25%) out of 8 patients with
hysical prophylaxis as well as three (25%) out of 12 patients with
ntiplatelet medication. Although no signiﬁcant difference was
etected, the mean age of DVT positive group tended to younger
han that of DVT negative group (75.1±9.3 vs. 81.1±10.8 years;
=0.078). Six (32%) out of 19 male patients and nine (36%) out of
5 female patients showed DVTs. No difference on DVT develop-
ent was observed in subgroup analysis for NYHA class (class III
s. IV).a Statistical testing methods are Fisher’s exact test for categorical data and Stu-
dent’s t-test for continuous data.
b For continuous data, the statistics are presented by mean± SD.
The summary of DVT conditions of 15 DVT positive patients is
listed in Table 4. The 15 DVT positive cases included three (20%)
proximal types (including popliteal vein) and three (20%) symp-
tomatic types. New thrombus was detected in 11 (25%) including
three with both new and old thrombus. Three patients were
treated: two out of 12 asymptomatic patients with unfractionated
heparin and warfarin, and one symptomatic out of 3 patients with
unfractionated heparin.
D-dimer of the 14 out of 15 patients with DVT was measured
at a time point within 2 days of US, and the D-dimer values were
higher than the standard cut-off value in all the samples.Discussion
This study is a multi-center, prospective, epidemiological study
to estimate the frequency of DVT in hospitalized non-surgical
H. Matsuo et al. / Journal of Card
Table 3
Results of comparison on prevalence of deep vein thrombosis (DVT) for important
parameters.
Categorical parameters
Parameter Classiﬁcation DVT prevalence (%) p valuea
Gender
Male 6/19 (31.6)
1.000Female 9/25 (36.0)
Age (years)
<75 6/14 (42.9)
0.501≥75 9/30 (30.0)
BMI (kg/m2)
<25 12/35 (34.3)
1.000≥25 3/9 (33.3)
Catheterization within
last 3 months
Yes 4/11 (36.4)
1.000No 11/33 (33.3)
NYHA classiﬁcation
Class III 7/14 (50.0)
0.177Class IV 8/30 (26.7)
Physical prevention
Yes 2/8 (25.0)
0.695No 13/36 (36.1)
Antiplatelet agent
Yes 3/12 (25.0)
0.500No 12/32 (37.5)
Concomitant diseases
of malignancy
Yes 2/7 (28.6)
1.000No 13/37 (35.1)
Continuous parameters (mean± SD)
Parameter DVT (+) (n=15) DVT (−) (n=29) p valueb
Age (years) 75.1 ± 9.3 81.1 ± 10.8 0.078
BMI (kg/m2) 21.4 ± 6.4 23.1 ± 6.4 0.404
Body weight (kg) 50.4 ± 14.4 54.7 ± 17.2 0.410
Systolic blood pressure
(mmHg)
127.2 ± 26.1 123.6 ± 20.8 0.619
Diastolic blood pressure
(mmHg)
66.5 ± 12.1 67.8 ± 18.8 0.801
Duration of rest (days) 9.1 ± 3.2 8.8 ± 3.2 0.792
BMI, body mass index; NYHA, New York Heart Association.
J
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diseases including atrial ﬁbrillation, valvular disease, or left ven-
T
S
Ta Fisher’s exact test.
b Student’s t-test.
apanese patients with CHF. Based on the diagnoses of lower
xtremity vein US, DVTs were identiﬁed in 15 patients out of 44
34.1%; 95% CI, 20.1–48.1%) in non-surgical patients with CHF.
Although the frequency of DVT in Japan has been recognized
s being lower than that overseas [1], the overall prevalence
f 34.1% and prevalence of newly formed thrombus of 25.0% in
apanese non-surgical patients with CHF are comparable with pre-
iously reportedprevalence inWesternpatients; 10–26%of general
able 4
ummary of deep vein thrombosis (DVT) conditions of 15 DVT positive patients with con
No. Location of thrombus New or old thrombus Symptoms
1 Proximal Old only None
2 Proximal Old only None
3 Proximal New only None
4 Distal Old only None
5 Distal Old only None
6 Distal New only None
7 Distal New only None
8 Distal New only None
9 Distal New only None
10 Distal New only None
11 Distal New and old None
12 Distal New only None
13 Distal New and old Edematous lower li
14 Distal New and old Swollen lower limb
15 Distal New only Swollen lower limb
effusion, peritoneal
he standard cut-off value of D-dimer is less than 1.0g/mL (0.9g/mL for two cases witiology 64 (2014) 430–434 433
in-hospital patients [4–6] and40% inpatientswithCHF [7]. Byusing
US, thrombus formed approximately within 1 week can be identi-
ﬁed as new while that formed 1 week ago or before can be detected
as old, and thus most of the newly formed thrombi identiﬁed by
US may have appeared after starting bed rest at the recruitment
for this study. Additionally, some patients developed DVT under
physical prophylaxis or anti-platelet medication. Nose et al. [13]
reported that popliteal venous ﬂow velocity in the CHF group was
signiﬁcantly attenuated compared to the control group in the res-
ting condition, suggesting that CHF patients have potential risks of
DVT. Our result suggests that additional approach including usage
of anticoagulant drugs to prevent DVT needs to be considered for
hospitalized non-surgical patients with CHF by adhering to DVT
prevention guidelines.
In this study, most of the patients with newly formed DVT were
not given any treatment. Ten out of 11 patients with new throm-
bus had distal vein thrombus. The remaining one patient with a
new thrombus had proximal vein thrombus, but the proximal end
was popliteal vein without symptoms. Based on these conditions
of DVT patients, immediate decision for medical intervention was
notmadeby thephysicians. InAmericanCollegeofChest Physicians
(ACCP) guideline, regularmonitoring of DVT rather than anticoagu-
lant therapy is recommended in patients with acute isolated distal
DVT of the leg and without severe symptoms or risk factors for
extension [14].
The strength of our study is conducting the standard testing pro-
cedure on lower extremity venous US employing a pre-determined
operation manual, training of study investigators and laboratory
technicians, and central read. This procedure ensured venous US
quality and minimized inter-investigating sites’ variation. By the
standardization of the procedure, US could be a good technique to
detect DVT with the advantage of non-invasiveness and low cost
over other imaging techniques. In fact, past imaging studies most
commonly usedUS and less frequently venography, CT scan, orMRI
[15]. The ACCP guideline for diagnosis of DVT recommends treating
DVT and performing no further testing over performing conﬁrma-
tory venography if the proximal vein is positive byUS, and suggests
no further testing if DVT is negative by US [15].
No associations betweenpotential risk factors andDVTdevelop-
ment were detected. This might be attributed to the limited size of
this study. In standard medical practice, most patients with hearttricular dysfunction received anticoagulation therapy [16,17], and
it may be difﬁcult to recruit the patients without treatment with
anticoagulation therapy.
gestive heart failure.
D-dimer value (g/mL) Treatment
9.20 None
5.6 None
19.90 None
1.43 None
7.10 None
8.39 None
Unmeasured None
2.36 None
3.1* None
5.1* None
15.48 Unfractionated heparin
3.5 Warfarin
mbs, fatigue 15.44 None
2.79 None
, edema, pleural
effusion
5.38 Unfractionated heparin
h asterisk (*)).
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Another limitation of this study would be the proﬁling of CHF
y only NYHA classiﬁcation. Further study including the proﬁl-
ng of CHF by objective indices including brain natriuretic peptide,
jection fraction and left ventricular end-diastolic dimension, and
xamination of associations between the objective indices andDVT
ccurrence may provide with additional information.
In conclusion, the frequency of DVT among Japanese hospi-
alized CHF patients (34.1%) is comparable to that in Westerners
nd also to that in Japanese post-operative patients in orthopedics
27.4–50.0%). This study has demonstrated that Japanese hospital-
zed patients with CHF have a high risk of DVT and thus can be
ecognized tohavepotential beneﬁtbypreventingand treatingDVT
ccording to the guidelines [9].
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